GlassScriptPhysician profile
Darshan P Godkar
NPI 1952515264
$194,043.30
in general payments reported to CMS, 2019-2025
58 companies · $39K in 2025
The $39K reported for 2025 was more than what 96% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $13K · 2021: $33K · 2022: $30K · 2023: $34K · 2024: $23K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Food and Beverage: $9,370 · Travel and Lodging: $2,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,950.75 |
| Food and Beverage | $9,370.34 |
| Travel and Lodging | $2,767.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $69,026.89 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59,837.65 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $18,874.24 | 2019-2022 | |
| Boston Scientific Corporation | $17,580.21 | 2019-2025 | Watchman, Watchman Access System, Watchman Flx |
| Lilly USA, LLC | $9,976.44 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic, INC. | $7,219.77 | 2021-2024 | Corevalve Evolut R, Onyx Frontier |
| Abbott Laboratories | $2,900.54 | 2020-2024 | Mitraclip, Jot Dx, Cardiomems |
| Edwards Lifesciences Corporation | $1,454.36 | 2019-2025 | Evoque, Pascal |
| Novartis Pharmaceuticals Corporation | $862.83 | 2019-2025 | |
| Penumbra, INC. | $793.92 | 2023 | Indigo System |
| Shockwave Medical, INC | $593.08 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Merck Sharp & Dohme LLC | $582.27 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $441.06 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $432.70 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $355.92 | 2019-2025 | Camzyos, Eliquis |
Show all 56 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darshan Godkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.